Merck, Inc.
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 322
- Registration Number
- NCT04924075
- Locations
- 🇨🇱
FALP ( Site 2200), Santiago, Region M. De Santiago, Chile
🇺🇸Cedars-Sinai Medical Center ( Site 0110), Los Angeles, California, United States
🇺🇸University of Iowa ( Site 0104), Iowa City, Iowa, United States
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
- Conditions
- Interventions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 81
- Registration Number
- NCT04907227
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University ( Site 1319), Xiamen, Fujian, China
🇨🇳Hunan Cancer Hospital ( Site 1320), Changsha, Hunan, China
🇨🇳The Second Affiliated Hospital of Zhejiang University School of Medicine ( Site 1309), Hangzhou, Zhejiang, China
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
- Conditions
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 340
- Registration Number
- NCT04895358
- Locations
- 🇺🇸
Parkview Research Center at Parkview Regional Medical Center ( Site 0071), Fort Wayne, Indiana, United States
🇺🇸University of Illinois at Chicago ( Site 0061), Chicago, Illinois, United States
🇫🇷Institut de Cancérologie de l'Ouest ( Site 0915), ANGERS cedex 02, Maine-et-Loire, France
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)
- Conditions
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 320
- Registration Number
- NCT04895722
- Locations
- 🇺🇸
University of Chicago Medical Center-Medicine - Section of Hematology/Oncology - Gastrointestinal P, Chicago, Illinois, United States
🇺🇸UPMC Hillman Cancer Center ( Site 1516), Pittsburgh, Pennsylvania, United States
🇨🇦The Moncton Hospital-Oncology ( Site 0307), Moncton, New Brunswick, Canada
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study
- Conditions
- Interventions
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 131
- Registration Number
- NCT04889118
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital (0609), Nanjing, Jiangsu, China
🇨🇳Beijing Cancer Hospital (0601), Beijing, Beijing, China
🇨🇳Sun Yat-Sen University Cancer Center (0602), Guangzhou, Guangdong, China
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
- Conditions
- Interventions
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT04882241
- Locations
- 🇨🇳
Afflilated Hospital of Bengbu Medical College-Surgical Oncology (Site 0638), Bengbu, Anhui, China
🇨🇳Tangdu Hospital of Fourth Military Medical University of Chinese People's Liberation Army ( Site 0647), Xi'an, Shaanxi, China
🇨🇳Beijing Friendship Hospital ( Site 0637), Beijing, Beijing, China
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
- Conditions
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 66
- Registration Number
- NCT04875195
- Locations
- 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site, Torrance, California, United States
🇨🇿Fakultni nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0302), Brno, Brno-mesto, Czechia
🇨🇿Fakultni nemocnice Kralovske Vinohrady-Interni hematologicka klinika ( Site 0303), Prague, Praha 10, Czechia
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
- Conditions
- Interventions
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 130
- Registration Number
- NCT04865289
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center ( Site 2500), Shanghai, Shanghai, China
🇨🇳Women s Hospital School of Medicine Zhejiang University ( Site 2511), Hangzhou, Zhejiang, China
🇨🇳Anhui Cancer Hospital-Gynecological Oncology ( Site 2509), Hefei, Anhui, China
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension
- Conditions
- Interventions
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT04859582
- Locations
- 🇨🇳
Peking Union Medical College Hospital ( Site 2425), Beijing, Beijing, China
🇨🇳Fujian Medical University Union Hospital ( Site 2410), Fuzhou, Fujian, China
🇨🇳900 Hospital of the Joint ( Site 2418), Fuzhou, Fujian, China
A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 52
- Registration Number
- NCT04846920
- Locations
- 🇺🇸
University of Michigan ( Site 1006), Ann Arbor, Michigan, United States
🇺🇸Beth Israel Deaconess Medical Center ( Site 1002), Boston, Massachusetts, United States
🇺🇸Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 1005), Nashville, Tennessee, United States